Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3541860 in Relapsing Multiple Sclerosis
NCT06220669Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- IgG Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of LY3541860 in multiple sclerosis (MS), sponsored by Eli Lilly and Company. Started Mar 2024; status: terminated.
02
Drugs
LY3541860
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06220669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220669.